|
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NOT_RECRUITINGPhase 3Sponsored by Eli Lilly and Company
No longer actively recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-05-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations35 sites
View on ClinicalTrials.gov →
NCT06972459
Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea, or * cardiovascular disease * Have a history of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have an unstable body weight within 90 days prior to screening * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * Have acute or chronic hepatitis or pancreatitis * Are taking other medications or alternative remedies to manage weight loss
Conditions3
DiabetesObesityOverweight
Interventions1
Locations35 sites
Clinical Research Institute of Arizona (CRI) - Sun City West
Jalal Abbas
Find trials near these locations
Related trials
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) — Eli Lilly and Company
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee — Eli Lilly and Company
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2025-05-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations35 sites
View on ClinicalTrials.gov →
NCT06972459